Breast cancer is the most common cancer and the second cause of cancer deaths worldwide. Consequentely there is an urgent need to develop new therapeutic agents and treatment strategies that are effective against this cancer. Treatment options for patients suffering from breast cancerare classicicaly based on cytotoxic chemotherapy or antiestrogen treatment. New treatment startegies are directed towards newly identified targets. Thus breast cancer treatment is getting more and more tumor type specific resulting in an improved outcome combined with new side effects.
In this special issue the authors will present the most innovative treatment strategies for breast cancer based on the molecular patholological character of the tumor like luminal A/B, triple negative and Her2 overexpressing breast cancer. Thus, innovative endocrine treatment options for example CDK 4/6 inhibitors and PI3K-inhibitors will be discussed for endocrine responsibel berast cancer. In triple negative breast cancer the importance of neoadjuvant treatment is presented combined with the newly accepted inhibition of the PDL1 pathway. In addition the meaningful results of PARP inhibition in BRCA mutated breast cancer are analyzed. For Her2 overexpressing breast cancer all treatment options of inhibiting this pathway with regard to the actual studies are presented for the neoadjuvant, adjuvant, post neoadjuvant and metastatic setting are presented. Last but not least the actual recommendations for oncologic and oncoplastic surgery including sentinel lymph node resection are discussed.
This issue should give a summary of the modern treatment strategies in breast cancer with a special aspect on the actual guidelines and recommendation of the new systemic treatment options.
Prof. Dr. Michael Friedrich and Dr. Nicolò Bertozzi
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.
Circulating Tumor Cells in Early Breast Cancer: Current Evidence and Perspectives
Feasibility of a Reduced Rate of Frozen Section Examination for Sentinel Node Biopsy in Breast Carcinoma
Clinical Advances in the Treatment of Hormone-receptor Positive Breast Cancer
Treatment Progress in Triple Negative Breast Cancer
Therapy Landscape in HER2-receptor Positive Breast Cancer
Dr. Med. M. Sellinger
Oncoplastic Surgery and Axillary Management in Primary Breast Cancer
Multigene Signatures in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer
Marcus Schmidt, Katrin Almstedt